作者: Robert S. Rosenson
DOI: 10.1007/978-1-60327-502-6_9
关键词: High-density lipoprotein 、 Randomized controlled trial 、 Therapeutic Lifestyle Changes 、 Niacin 、 Dyslipidemia 、 Internal medicine 、 Clinical trial 、 Medicine 、 Statin 、 Hypoalphalipoproteinemia
摘要: Primary hypoalphalipoproteinemia is characterized by isolated low levels of high-density lipoprotein cholesterol (HDL-C) below the tenth percentile compared with age- and gender-matched controls. Low HDL-C are associated an increased risk coronary heart disease (CHD) in epidemiologic studies, randomized clinical trials statin therapy identified patients at cardiovascular events, even when low-density (LDL-C) less than 70 mg/dL. Raising therapeutic lifestyle changes pharmacologic intervention might afford opportunities to further reduce CHD beyond LDL-C lowering. Statins first-line pharmacotherapy for treatment dyslipidemia events statins can also improve levels, although extent which they modify varies. Combining niacin raises more a alone this combination has been shown atherosclerosis two small-scale trials. One large-scale trial initiated investigate efficacy statin–niacin monotherapy.